BPBiswa Mohan Padhy

Biswa Mohan Padhy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Biswa Mohan Padhy has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Regimen-stratified Bayesian model-based meta-analysis of targeted biologics in generalised myasthenia gravis: efficacy comparison, mechanism-level class contrast, and endpoint sensitivity with model-informed trial design

    by Sayantan Shankar Roy, Biswa Mohan Padhy, Abhishek Anil, Debasish Hota, Anand Srinivasan, Apoorva Wasnik

    Nine targeted biologics spanning four mechanisms have reached phase III development for generalised myasthenia gravis, yet no cross-programme comparison accounts for the distinct continuous versus cyclical dosing patterns or integrates both patient-reported (MG-ADL) and clinician-assessed (QMG) scales. We performed a regimen-stratified Bayesian model-based meta-analysis (MBMA) to compare efficacy, evaluate mechanism-level class differences, and inform trial design. Longitudinal MG-ADL and QMG data were extracted from nine placebo-controlled phase III trials. Six hierarchical nonlinear Emax models were fitted with inverse-variance weighting. Drug-specific maximum efficacy, net benefit over placebo, week 26 predictions, time to the minimum clinically important difference (MCID), cumulative efficacy, ranking probabilities, and mechanism-level class contrasts were derived. Robustness was assessed via model comparison, prior sensitivity, and Leave-one-study-out analyses on both scales. Endpoint-sensitivity simulation and a treatment-selection framework were appended. The study was registered with PROSPERO: CRD420261288549. On MG-ADL, zilucoplan led with the highest Emax (4.8 points; 95% CrI: 4.2–5.4) and largest net benefit (2.5; 2.0–3.1). On QMG, batoclimab led (Emax 5.9; 4.4–9.5; net benefit 4.1; 2.7–7.7). Efgartigimod achieved the fastest onset on both scales (≤ 1.6 weeks). At the mechanism class level, neonatal Fc receptor (FcRn) inhibitors demonstrated decisive superiority over complement inhibitors on QMG (mean Emax 5.28 vs 3.99; posterior probability 99.7%) while no class difference was observed on MG-ADL (52.5%), identifying a scale-dependent mechanism–efficacy dissociation. The regimen-stratified architecture was decisively favoured over a pooled model (Δ Expected log pointwise predictive density [ELPD] = + 19.8). Drug rankings were invariant across prior specifications and Leave-one-study-out permutations on both scales (maximum rank shift: 1 position). For rozanolixizumab on MG-ADL, snapshot week 26 endpoints were underpowered (65%); integrated endpoints recovered power to 94–95%. In the treatment-selection framework, batoclimab held the highest composite score in all eight priority profiles, while the identity of the runner-up varied with clinical priority. This analysis identifies a novel scale-dependent mechanism-level class effect — FcRn inhibitors outperform complement blockade on objective motor endpoints with near-certainty, while both classes improve patient-reported function equally. Across the multi dimensional treatment-selection framework integrating efficacy, safety, tolerability, and convenience, batoclimab emerged as the highest-ranked agent in all eight clinical priority profiles. These findings provide a pharmacodynamic evidence base for mechanism-guided treatment individualisation and endpoint optimisation in generalised myasthenia gravis.

  • Efficacy of botulinum toxin type a for treating chronic low back pain: a systematic review and metanalysis

    by Bharath Kumar G, Mantu Jain, Bikash Ranjan Meher, Biswa Mohan Padhy, Harshal Sakale, Santosh Kumar

    Background Chronic low back pain (CLBP) is a leading cause of pain and disability worldwide. Most cases are nonspecific, lacking a clear pathological cause, and management remains challenging. Botulinum toxin type A (BoNT-A), a neurotoxin that blocks acetylcholine release and reduces muscle hyperactivity, has been studied in CLBP with inconsistent results. This meta-analysis aimed to determine the efficacy of BoNT-A compared with placebo or saline in the management of nonspecific CLBP. Methods A comprehensive search of PubMed, Embase, Cochrane Library, and the WHO ICTRP databases was conducted for randomized controlled trials (RCTs) involving adults with nonspecific CLBP who received BoNT-A or placebo injections and were registered in PROSPERO (CRD42024559735). The primary outcome was pain response, defined as a ≥ 50% reduction in VAS score, while the secondary outcome was functional improvement. A random-effects model was used to calculate pooled risk ratios (RR) with 95% confidence intervals (CI). Results Five eligible RCTs involving 177 participants were analyzed. BoNT-A improved pain response compared with placebo [RR = 2.09, 95% CI: 1.11–3.95; p = 0.02; I2 = 62%]. Functional outcomes also favored BoNT-A [RR = 2.25, 95% CI: 1.09–4.67; p = 0.03; I2 = 69%]. Sensitivity analyses confirmed robustness. Exploratory meta-regression suggested a possible decrease in pain effect with longer follow-up, while functional outcomes showed no significant association; dose was not a significant moderator. Risk of bias was low in one trial, some concerns in three, and high in one. Certainty of evidence was low for both outcomes. Conclusion BoNT-A may improve pain and functional outcomes in nonspecific CLBP, although the certainty of evidence is low. Exploratory analyses suggested a possible decline in pain benefit over time, and safety data are limited. Larger, high-quality RCTs are needed to confirm these findings.


  • Medication error reporting among health care providers - Practices, attitudes, facilitators, and barriers: A mixed-method study

    by Renju Sussan Baby, Jawahar S.K. Pillai, Biswajeevan Sahoo, Ramkrishna Mondal, Biswa Mohan Padhy, Kalesh M. Karun, Dharamveer Choudhary, Manoj Thampy, Geetanjali Singh, Virendra Kumar Yadav

  • Open Access

    Radiation-induced Skin Necrosis Following Intra-articular Yttrium-90 Hydroxyapatite in a Patient with Chronic Knee Synovitis

    by Krishna Nikhila Bonga, Kanhaiyalal Agrawal, Parneet Singh, Biswa Mohan Padhy

    Radionuclide synovectomy using Yttrium-90 hydroxyapatite has been shown to be a safe and effective treatment for patients with chronic synovitis. However, cutaneous radiation necrosis is a rare complication of this procedure. Potential causes include improper radionuclide injection, leakage, or extra-articular deposition. Early recognition of this adverse effect is critical for implementing an appropriate treatment strategy and avoiding unnecessary interventions. This case report presents an instance of radiation-induced skin necrosis following intra-articular administration of Yttrium-90 in a patient with chronic knee synovitis.

  • Analgesic efficacy of ultrasound-guided erector spinae plane block versus costotransverse foramen block in patients with chest trauma: A randomized controlled study

    by Aditya Vikram Prusty, Anju Gupta, Chitta Ranjan Mohanty, Biswa Mohan Padhy, Shantanu Kumar Sahu, Rakesh Vadakkethil Radhakrishnan, Amiya Kumar Barik, Sangeeta Sahoo, Upendra Hansda, Subhasree Das, et al.


  • Effectiveness and safety of radionuclide synovectomy with Yttrium-90 hydroxyapatite in patients with inflammatory arthritis: a longitudinal study

    by Krishna Nikhila Bonga, Kanhaiyalal Agrawal, Sujit Kumar Tripathy, Bikash Ranjan Meher, Archana Mishra, Biswa Mohan Padhy

    Background and objective: Yttrium-90 plays a significant role in managing drug-resistant inflammatory arthritis through radionuclide synovectomy, where the radioisotope is injected into the affected joint to alleviate pain and inflammation by targeting the synovial tissue. This study aims to evaluate the effectiveness and safety of Yttrium-90 hydroxyapatite radionuclide synovectomy in improving joint functionality, as judged by physicians, in patients with inflammatory arthritis who had not responded to conventional treatments. Methods: Patients with inflammatory arthritis were recruited from the orthopedics department and referred to the nuclear medicine department for evaluation. A three-phase bone scan was conducted to identify eligible patients, who then received intra-articular injections of Yttrium-90 hydroxyapatite along with triamcinolone. After 48 h, patients underwent PET-CT imaging, followed by two follow-ups at 2 and 6 months to assess improvements in joint functionality and monitor for adverse reactions. Results: Fifteen patients underwent radionuclide synovectomy. Significant improvements were observed between baseline and 2 months in joint restriction (P = 0.001), pain severity (P = 0.037), visual analog scale (VAS) (P = 0.004), and swelling (P = 0.002). At 6 months, further improvements were noted in joint restriction (P = 0.002), pain severity (P = 0.019), VAS (P = 0.013), and swelling (P = 0.023). However, no significant changes occurred between the 2- and 6-month follow-ups. One patient experienced radiation-induced skin necrosis, which resolved with conservative treatment, and another had self-limited skin rashes. Conclusion: Yttrium-90 hydroxyapatite radionuclide synovectomy proved to be an effective and safe treatment for improving joint functionality in patients with drug-resistant inflammatory arthritis of the knee for up to 6 months.


  • Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms

    by Krishna Nikhila Mbbs Bonga, Archana Dm Mishra, Rituparna Maiti, Biswa Mohan Dm Padhy, Bikash Ranjan Meher, Anand Dm Srinivasan

    OBJECTIVE: To evaluate the efficacy and adverse events of fezolinetant for treating vasomotor symptoms (VMS) of menopause. DATA SOURCES: PubMed/MEDLINE, ClinicalTrials.gov, EMBASE, Cochrane Database, Scopus, and WHO International Clinical Trials Registry Platform were searched through June 2023 for publications and randomized controlled trials on fezolinetant compared with placebo in menopausal women who experienced moderate-to-severe VMS. METHODS OF STUDY SELECTION: Our literature search identified 330 articles, of which five studies with six reports were included in our meta-analysis per our eligibility criteria. TABULATION, INTEGRATION, AND RESULTS: The risk of bias was evaluated using Cochrane's RoB 2 (Risk of Bias version 2) tool, quality of evidence was graded using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach, and outcome measures data for effect size were pooled in random-effects model and rated. A total of 2,168 participants from five randomized clinical trials (six reports) were included. Fezolinetant significantly lowered VMS frequency, with pooled mean difference of 2.62 (95% CI, 1.84–3.41). The pooled mean difference for fezolinetant compared with placebo for the MENQOL (Menopause-Specific Quality of Life) measure was −0.60 (95% CI, −0.92 to −0.28), and the mean percentage improvement in VMS frequency was 22.51% (95% CI, 15.35–29.67). Fezolinetant was associated with improvement in sleep quality when compared with placebo. CONCLUSION: Fezolinetant is effective in lowering moderate-to-severe VMS frequency and sleep disturbances in postmenopausal women. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42023427616.


  • A Placebo-Controlled, Double-Blind Clinical Investigation to Evaluate the Efficacy of a Patented Trigonella foenum-graecum Seed Extract “Fenfuro®” in Type 2 Diabetics

    by Debasish Hota, Biswa M. Padhy, Rituparna Maiti, Debasis Bisoi, Jyoti Prakash Sahoo, Binod K. Patro, Pawan Kumar, Apurva Goel, Samudra P. Banik, Sanjoy Chakraborty, et al.

    Trigonella foenum-graecum (Fenugreek) is an extensively researched phytotherapeutic for the management of Type 2 diabetes without any associated side effects. The major anti-diabetic bioactive constituents present in the plant are furostanolic saponins, which are more abundantly available in the seed of the plant. However, the bioavailability of these components depends on the method of extraction and hence formulation of the phytotherapeutic constitutes a critical step for its success. The present study reports the efficacy of a novel, patented fenugreek seed extract, Fenfuro®, containing significant amount of furostanolic saponins, in an open-labelled, two-armed, single centric study on a group of 204 patients with Type 2 diabetes mellitus over a period of twelve consecutive weeks. Administration of Fenfuro® in the dosage of 500 mg twice daily along with metformin and/or sulfonylurea-based prescribed antidiabetic drug resulted in a reduction of post-prandial glucose by more than 33% along with significant reduction in fasting glucose, both of which were greater than what resulted for the patient group receiving only Metformin and/or Sulfonylurea therapy. Fenfuro® also resulted in reduction in mean baseline HOMA index from 4.27 to 3.765, indicating restoration of insulin sensitivity which was also supported by a significant decrease in serum insulin levels by >10% as well as slight reduction in the levels of C-peptide. However, in the case of the Metformin and/or Sulfonylurea group, insulin levels were found to increase by more than 14%, which clearly indicated that drug-induced suppression of glucose levels instead of restoration of glucose homeostasis. Administration of the formulation was also found to be free from any adverse side effects as there were no changes in hematological profile, liver function and renal function. The study demonstrated the promising potential of this novel phytotherapeutic, Fenfuro®, in long-term holistic management of type-2 diabetes.


  • Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials

    by Bikash Ranjan Meher, Rashmi Ranjan Mohanty, Biswa Mohan Padhy

    Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disorder. Though, corticosteroids are the cornerstone of therapy, the Janus kinase inhibitor abrocitinib has shown promise in recent ...